Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Veritas In Silico Inc. ( (JP:130A) ) has provided an update.
SpiroChem AG and Veritas In Silico have signed a Joint Research Agreement to discover next-generation mRNA-targeting small molecule drug candidates. The collaboration combines SpiroChem’s medicinal chemistry and complex modality expertise in macrocycles, peptides and peptoids with Veritas In Silico’s AI-based aibVIS platform and cellular assay capabilities to advance RNA-binding chemical matter.
The partners intend to monetize successful research outputs through joint licensing to third parties or co-development arrangements, signaling a move to build a commercial pipeline around mRNA-targeted compounds. The agreement follows a prior memorandum of understanding signed in January 2026, and the companies are already planning discussions for a subsequent research phase, underscoring a longer-term strategic partnership in RNA-targeted therapeutics.
More about Veritas In Silico Inc.
Veritas In Silico Inc. is a Tokyo-based biotech company listed on the TSE Growth market that specializes in AI-driven mRNA-targeted drug discovery. Its core platform, aibVIS, uses artificial intelligence and cellular assays to design small molecule therapeutics aimed at RNA, positioning the firm in the emerging field of mRNA-binding medicines.
Average Trading Volume: 32,530
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.01B
See more insights into 130A stock on TipRanks’ Stock Analysis page.